The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of epacadostat (INCB024360) added to preoperative chemoradiation in patients with locally advanced rectal cancer.
 
Moh'd Khushman
Stock and Other Ownership Interests - Cardiff Oncology
Consulting or Advisory Role - Abbvie; bristol-myers squibb; Cardinal Health; Elevar Therapeutics; Exelixis; Muerus; TriSalus Life Sciences
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbvie (Inst); FOGPharma (Inst); IgM Biosciences (Inst); Torl Biotherapeutics (Inst)
 
Haeseong Park
Consulting or Advisory Role - Merck
Research Funding - Amgen (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); D3Bio (Inst); Exelixis (Inst); Huoata Bio (Inst); Idience (Inst); Incyte (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Strata Oncology (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Katrina Pedersen
Honoraria - OncLive/MJH Life Sciences; Takeda; WebMD/Medscape; WebMD/Medscape (Inst)
Consulting or Advisory Role - Agenus; Array BioPharma; Artemida Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; GlaxoSmithKline; Guardant Health; Incyte; Novartis; Pfizer; SAGA Diagnostics; Taiho Oncology; Taiho Oncology; Takeda (Inst); Tempus
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Biomea Fusion (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Daiichi Sankyo/Lilly (Inst); HCW Biologics (Inst); Incyte (Inst); Ipsen (Inst); Natera (Inst); Nouscom (Inst); Novartis (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Array BioPharma; BeiGene; GlaxoSmithKline; NCCN; Nouscom
Other Relationship - UpToDate
(OPTIONAL) Uncompensated Relationships - NCCN
 
Kian-Huat Lim
Honoraria - CURIS
Patents, Royalties, Other Intellectual Property - Hold patent for targeting MK2 as a therapeutic strategy in pancreatic cancer.
 
Nikolaos Trikalinos
Research Funding - Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Nykode Therapeutics (Inst)
 
Benjamin Tan
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Tvardi Therapeutics (Inst); TYME (Inst)
 
Olivia Aranha
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Seagen
Research Funding - AstraZeneca (Inst); Compass Therapeutics (Inst)
 
Rama Suresh
No Relationships to Disclose
 
Michael Iglesia
No Relationships to Disclose
 
Nikolaos Andreatos
No Relationships to Disclose
 
Patrick Grierson
Employment - Walgreens (I)
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer
 
Matthew Mutch
No Relationships to Disclose
 
William Chapman
No Relationships to Disclose
 
Steven Hunt
No Relationships to Disclose
 
Michelle Cowan
No Relationships to Disclose
 
Paul Wise
No Relationships to Disclose
 
Hyun Kim
Honoraria - Varian Medical Systems; ViewRay
Consulting or Advisory Role - Novartis; Varian Medical Systems
Research Funding - Varian Medical Systems; ViewRay
Travel, Accommodations, Expenses - Elekta; Varian Medical Systems; ViewRay
 
Allen Mo
No Relationships to Disclose
 
Jingxia Liu
No Relationships to Disclose
 
Matthew Ciorba
No Relationships to Disclose